(Q47187857)

11 January 2018

title

Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin (English)

1 reference

11 January 2018

0 references

1 reference

S Grandy

1

1 reference

11 January 2018

M Hashemi

2

1 reference

11 January 2018

A-M Langkilde

3

1 reference

11 January 2018

S Parikh

4

1 reference

11 January 2018

C D Sjöström

5

1 reference

11 January 2018

publication date

9 February 2014

1 reference

11 January 2018

Diabetes, Obesity and Metabolism

published in

1 reference

11 January 2018

volume

16

1 reference

11 January 2018

issue

7

1 reference

11 January 2018

page(s)

645-650

1 reference

11 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

cites work

1 reference

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin.

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus

21 January 2018

1 reference

21 January 2018

1 reference

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement.

21 January 2018

1 reference

Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12263

1 reference

11 January 2018

1 reference

11 January 2018